Media

The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi

Details
Andrea Necchi, a medical oncologist and Ewan Gibb a researcher at Decipher Biosciences joins Alicia Morgans as they discuss new findings related to bladder cancer and the impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer, an area of unmet need in bladder cancer. The trio cover patient sel...

Outpatient Trans-Rectal MR-Guided Laser Focal Therapy Phase II Clinical Trial: 10-Year Interim Results - John Feller

Details
John Feller presents at the Focal Therapy and Imaging in Prostate and Kidney Cancer Symposium, sharing interim 10-year results of the Phase II trial of Laser Focal Therapy for prostate cancer. This involves an outpatient trans-rectal laser therapy guided with an MRI imaging system. 95% of patients were biopsy compliant at 6 months and 94% avoided whole gland therapy and associated morbidity. The r...

Focal Therapy in Prostate Cancer - Art Rastinehad

Details
Prostate cancer survivor John Fortin is joined by Art Rastinehad a professor of urology and radiology at Mount Sinai to discuss targeted therapies for prostate cancer. Together they discuss when patients are recommended to active surveillance, versus when they must receive more complex treatment regimes. They discuss the research done to identify and test focal therapies for prostate cancer. Dr. R...

The Evolution of Care: Focal Therapy for Prostate Cancer: Tom Polascik

Details
Tom Polascik, a urologic oncologist with considerable experience in treating both kidney and prostate cancer and the founder of the Focal Therapy Society joins John Fortin providing a background of the Focal Therapy society and the 12th International Symposium on focal therapy and imaging in prostate and kidney cancer. He shares the concept of the society and summarizes the evolution of care in pr...

The COVID-19 Pandemic Impacting GU Cancer Care in London - Tom Powles

Details
Recorded Date: April 23, 2020 Thomas Powles from Barts Cancer Institute in London joins Alicia Morgans in a follow-up discussion providing an update to a previously recorded conversation on the current healthcare environment during the Coronavirus disease 2019 (COVID-19),(SARS-CoV-2) pandemic in the United Kingdom. Dr. Powles shares an aspirational perspective from London looking towards the futur...

Alternative Strategies to Deliver Bladder Cancer Investigation During COVID-19 and Beyond - Neal Shore

Details
Recorded Date: April 18, 2020 Many of the tests used to diagnose and detect bladder cancer involve invasive procedures. Non-invasive testing options are equally effective and can be applied in this COVID-19 environment where we want to limit patients needing to come into the clinics for tests. In this discussion Neal Shore, Sima Porten, and Tom Nifong discuss Cxbladder a non-invasive, urine-based...

The Ethics of Delivering Precision Medicine — Hala Borno

Details
Hala Borno joins Alicia Morgans and discusses a recent viewpoint article in JAMA Oncology titled “The Ethics of Delivering Precision Medicine—Pretest Counseling and Somatic Genomic Testing.” In the new era of precision medicine in cancer treatment, many clinicians use patient tumor genomic (somatic) data as part of routine clinical practice. Dr. Borno shares insights into Pretest Counseling in an...

Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland

Details
Stephen Freedland joins Alicia Morgans to discuss the Carbohydrate and Prostate Study 2 (CAPS2), a randomized controlled trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer. This study is part of a series of studies looking at the role of low carbohydrate diets in prostate cancer. The study involved taking men with rising PSA after failed s...

NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer

Details
Recorded Date: March 30, 2020 Edward (Ted) Schaeffer provides the urologist's perspective while answering patient questions on treatment considerations for localized prostate cancer in light of the COVID-19 crisis. Dr. Schaeffer provides insights into the National Comprehensive Cancer Network (NCCN) new patient guidelines on April 1, 2020. Biographies: Edward M. Schaeffer, MD, Ph.D., Chair, Depart...

NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans

Details
Recorded Date: March 30, 2020 The National Comprehensive Cancer Network (NCCN) released new guidelines, on April 1, 2020, directing cancer care during the COVID-19 crisis, Alicia Morgans and Edward Schaeffer address patient questions about their primary treatment concerns during this unprecedented time. Biographies: Edward M. Schaeffer, MD, Ph.D., Chair, Department of Urology, Feinberg School of M...